CFO
HRMY icon

Callan Family Office’s Harmony Biosciences HRMY Stock Holding History

Callan Family Office’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$437K Buy
15,584
+2,359
+18% +$77.4K 0.01% 816
2025
Q4 		$495K Buy
13,225
+5,821
+79% +$191K 0.01% 786
2025
Q3 		$204K Sell
7,404
-4,209
-36% -$145K 0.01% 821
2025
Q2 		$367K Buy
+11,613
New +$374K 0.01% 705

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Callan Family Office's HRMY Position: Q1 2026 in Review

Callan Family Office increased its Harmony Biosciences (HRMY) stake by 18% in Q1 2026, buying an estimated $77.4K and bringing the position to 15,584 shares worth $437K. The position accounts for 0.01% of the portfolio, ranked #816.

Callan Family Office first reported a position in HRMY in Q2 2025 and has held it in 4 quarters since. The position peaked at $495K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Callan Family Office held 15,584 shares of Harmony Biosciences worth $437K as of Q1 2026.
  • Callan Family Office bought 2,359 Harmony Biosciences shares in Q1 2026, an estimated $77.4K.
  • Harmony Biosciences made up 0.01% of Callan Family Office's portfolio in Q1 2026, its #816 holding.
  • Callan Family Office first reported a position in Harmony Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Callan Family Office's Harmony Biosciences position peaked at $495K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.